Stevanato Group Q3 revenue beats estimates on biopharma segment
STVN•Stevanato Group’s third-quarter revenue rose 8% to €326.1 million, above analyst expectations of €320.93 million, while adjusted diluted EPS increased 14% to €0.16. The company maintained its 2026 revenue guidance of €1.26 billion to €1.28 billion and expects low single-digit revenue growth in 2027.
1. Quarterly results
Stevanato Group reported third-quarter revenue of €326.1 million, up 8% and above the €320.93 million analyst consensus. Adjusted diluted EPS rose 14% to €0.16.
2. Segment performance
Organic revenue in Biopharmaceutical and Diagnostic Solutions increased 11%, driven by high-value and other containment and delivery solutions. Engineering Segment revenue fell 12%, mainly on lower sales of pharma visual inspection, assembly and packaging. CEO Franco Stevanato said growth of more than 30% in non-GLP-1 biologics demand offset lower GLP-1 therapy revenue.
3. 2026 and 2027 outlook
The company maintained its 2026 revenue guidance of €1.260 billion to €1.280 billion and expects adjusted EBITDA of €335.0 million to €345.2 million. It anticipates low single-digit revenue growth in 2027 due to lower GLP-1 volumes.
